Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer

Published:2015-07 Issue:7 Volume:10 Page:1099-1106
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Foster Nathan R.,Renfro Lindsay A.,Schild Steven E.,Redman Mary W.,Wang Xiaofei F.,Dahlberg Suzanne E.,Ding Keyue,Bradbury Penelope A.,Ramalingam Suresh S.,Gandara David R.,Shibata Taro,Saijo Nagahiro,Vokes Everett E.,Adjei Alex A.,Mandrekar Sumithra J.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference47 articles.

1. Cancer statistics, 2014;Siegel;CA Cancer J Clin,2014

2. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702;Okamoto;Br J Cancer,2007

3. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group;Roth;J Clin Oncol,1992

4. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent;Pujol;Br J Cancer,2000

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular epidemiology study of programmed death ligand 1 and ligand 2 protein expression assessed by immunohistochemistry in extensive-stage small-cell lung cancer;Frontiers in Oncology;2024-01-09

2. Association Between Intermediate End Points, Progression-free Survival, and Overall Survival in First-line Advanced or Recurrent Endometrial Cancer;Clinical Therapeutics;2023-10

3. Radiotherapy for extensive-stage small-cell lung cancer in the immunotherapy era;Frontiers in Immunology;2023-08-28

4. Total Metabolic Tumor Volume on 18F-FDG PET/CT Is a Useful Prognostic Biomarker for Patients with Extensive Small-Cell Lung Cancer Undergoing First-Line Chemo-Immunotherapy;Cancers;2023-04-10

5. Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings;BMC Cancer;2022-09-29